Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 1/2018

Open Access 01-12-2018 | Letter

The mechanism of action of the adrenomedullin-binding antibody adrecizumab

Authors: Christopher Geven, Peter Pickkers

Published in: Critical Care | Issue 1/2018

Login to get access

Excerpt

With interest we read the review by Levy et al. [1] that provides a thorough overview of current and future therapies aiming to treat vasoplegia, an ubiquitous phenomenon in shock. In their work, the authors dedicated a section to the novel adrenomedullin (ADM)-binding antibody adrecizumab, which is mentioned as an ADM blocking compound in the section title. Recently published studies demonstrate that blocking of ADM does not accurately describe adrecizumab’s mechanism of action, though. …
Literature
1.
Levy B, Fritz C, Tahon E, Jacquot A, Auchet T, Kimmoun A. Vasoplegia treatments: the past, the present, and the future. Crit Care. 2018;22:52.CrossRefPubMed
2.
Struck J, Hein F, Karasch S, Bergmann A. Epitope specificity of anti-Adrenomedullin antibodies determines efficacy of mortality reduction in a cecal ligation and puncture mouse model. Intensive Care Med Exp. 2013;1:22.CrossRefPubMed
3.
4.
Geven C, van Lier D, Blet A, Peelen R, ten Elzen B, Mebazaa A, et al. Safety, tolerability and pharmacokinetics/-dynamics of the adrenomedullin antibody Adrecizumab in a first-in-human study and during experimental human endotoxemia in healthy subjects. Br J Clin Pharmacol. 2018; https://​doi.​org/​10.​1111/​bcp.​13655.
5.
Metadata
Title
The mechanism of action of the adrenomedullin-binding antibody adrecizumab
Authors
Christopher Geven
Peter Pickkers
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2018
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-018-2074-1

Other articles of this Issue 1/2018

Critical Care 1/2018 Go to the issue

Research

Evaluation of a real-time PCR assay for detection and quantification of bacterial DNA directly in blood of preterm neonates with suspected late-onset sepsis

Letter

Microcirculation in cardiogenic shock supported with extracorporeal membrane oxygenation: the need for a homogeneous population and strict evolution assessment

Research

Antimicrobial exposure and the risk of delirium in critically ill patients

Research

Impact of timing of continuous intravenous anesthetic drug treatment on outcome in refractory status epilepticus

Letter

Adjuvant Vitamin C in critically ill patients undergoing renal replacement therapy: What’s the right dose?

Letter

Response to Gunst and Casaer on the letter to the editor “Is the protein intake saturated at doses recommended by the feeding guidelines for critically ill patients?”